For example, antitubercular hydrophilic drugs such as isoniazid and pyrazinamide which are orally active showed sustained drug release from the tyloxapol niosome membrane .
Jindal, "Formulation of Tyloxapol niosomes for encapsulation, stabilization and dissolution of anti-tubercular drugs," Colloids and Surfaces B: Biointerfaces, vol.
Westesen, "P234 solid lipid nanoparticles stabilized by tyloxapol
," European Journal of Pharmaceutical Sciences, vol.
The administration of the nonionic detergent, triton WR1339 (Tyloxapol
), was able to increase the oxidative markers in animals.
Tenders are invited for Supply of Drop Brinzlamine 10 Mg Activate Inactivated Benzalkonium Chloride Ep 10 Mg, Mannitol Carbopol 974 P, Tyloxapol
, Disodium Acetate, Sodium Chloride, Sodium Hydroxide For Eye In 5 Ml Ph.
Ramachandran, "Antihyperlipidemic potential of a polyherbal preparation on Triton WR1339 (Tyloxapol
) induced hyperlipidemia: a comparison with lovastatin," International Journal of Green Pharmacy, vol.
Assim, o objetivo deste estudo foi de avaliar o efeito do tratamento com oleo de linhaca, em diferentes doses e dias na dislipidemia induzida por triton WR 1339 (tyloxapol
) em ratos wistar.
Although there are only a limited number of such products, one example is Blink-N-Clean (Abbott Medical Optics Inc, Santa Ana, California, USA), which contains the surfactant Tyloxapol
and edetate disodium as a chelating agent.
Rats in groups 2 to 4 received a single intravenous injection of triton WR 1339 (tyloxapol) (850 mg/kg;.iv.) while rats in negative control group received an injection of saline solution 9% through the same route.
Effect of Guibourtia tessmannii extracts on blood lipids and oxidative stress markers in triton WR-1339 induced hyperlipidemic rats Administration of tyloxapol (triton WR-1339) caused a significant increase (p<0.05) in plasma total cholesterol and triglyceride of tritonized group as compared to animals in the control group.
One of the first available protein-free, artificial surfactant preparations was Exosurf, or colfosceril palmitate plus cetyl alcohol and tyloxapol
. A 1991 paper by Dechant and Faulds noted that in a large clinical trial, babies diagnosed with respiratory distress syndrome who were treated with Exosurf had fewer pneumothoraces, and survivors had less incidence of bronchopulmonary dysplasia.
Although the patients received nebulised salbutamol and tyloxapol
(a mucolytic agent) at four-hour intervals, insufficient humidification of the jet stream contributed to the formation of extremely tenacious secretions.